Strides Arcolab’s subsidiary receives US FDA approval for Carboplatin Injection

11 Nov 2011 Evaluate

Strides Arcolab's wholly owned subsidiary Onco Therapies, has received US FDA approval for Carboplatin Injection 10 mg/mL packaged in 50mg/mL, 150mg/mL, 450 mg/45 mL and 600 mg/60 mL Multi-dose vials. According to IMS June 2011, the US market for generic Carboplatin is approximately $35 million. Carboplatin is a part of Oncology portfolio licensed to Pfizer in January 201for US market and expected to be launched shortly.

Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents, and in secondary treatment of advanced ovarian carcinoma which has recurred after prior chemotherapy.

Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufacturers a wide range of IP-led niche pharmaceuticals products with an emphasis on sterlite injectables.

Strides Pharma Scien Share Price

671.25 34.80 (5.47%)
05-May-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1835.15
Dr. Reddys Lab 1172.50
Cipla 1543.10
Lupin 2087.30
Zydus Lifesciences 892.15
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...